Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis.

Adv Ther · 2021 · PMC8107152 · PMID 33768419

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients with higher body weight showed a trend of higher cemiplimab exposure with 3 mg/kg Q2W; the trend was reversed for 350 mg Q3W.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.